Browse > Article
http://dx.doi.org/10.5806/AST.2021.34.5.212

Method development and validation of spectrophotometric and RP-HPLC methods for simultaneous estimation of spironolactone and furosemide in bulk and combined tablet dosage forms  

Chavan, Rohankumar R. (Dept. of Pharmaceutical Chemistry, Bharati Vidyapeet College of Pharmacy)
Bhinge, Somnath D. (Dept. of Pharmaceutical Chemistry, Rajarambapu College of Pharmacy)
Bhutkar, Mangesh A. (Dept. of Pharmaceutics, Rajarambapu College of Pharmacy)
Randive, Dheeraj S. (Dept. of Pharmaceutics, Rajarambapu College of Pharmacy)
Salunkhe, Vijay R. (Dept. of Pharmacognosy, Rajarambapu College of Pharmacy)
Publication Information
Analytical Science and Technology / v.34, no.5, 2021 , pp. 212-224 More about this Journal
Abstract
The intent of the present work was to develop a simple, sensitive, accurate, precise, rapid and economical UV- spectrophotometric and reverse phase high pressure liquid chromatographic method for the simultaneous estimation of Spironolactone and Furosemide in bulk and combined tablet dosage forms. UV-Spectrophotometry was carried out by simultaneous equation method using 0.02 M potassium dihydrogen phosphate buffer pH 3.5: Acetonitrile (50:50) v/v as a solvent. The linearity range was 2-14 ㎍ mL-1 for Spironolactone and Furosemide with a correlation coefficient > 0.99. The chromatographic separation was achieved on 250 mm × 4.6 mm, hypersil BDS C18 column with particle size 5 ㎛, by using an isocratic mixture of 0.02 M potassium dihydrogen phosphate buffer pH 3.5: Acetonitrile: tert butyl methyl ether (49:50:1) v/v/v as a solvent at a flow rate of 1 mL min-1 and UV detection was carried out at 254 nm. The retention time were observed to be 3.666 and 6.661 minutes for Furosemide and Spironolactone respectively. The two developed methods were validated according to the ICH guidelines for accuracy, precision, linearity, LOD, LOQ and were found to be within the limits. It can be concluded that these two methods could be successfully used for the simultaneous estimation of Spironolactone and Furosemide in bulk and combined tablet dosage forms.
Keywords
UV-spectroscopic; RP-HPLC; spironolactone; furosemide;
Citations & Related Records
연도 인용수 순위
  • Reference
1 M. Bhojani, K. Dadhania and S. Faldu, Journal of Pharmaceutical Science and Bioscientific Research, 2, 144-147 (2012).
2 S. S. Israt, M. N. Uddin, R. A. Jahan and M. M. Karim, Bangladesh J. Sci. Indust. Res., 51, 297-306 (2016).   DOI
3 P. Parimoo, A. Bharathi and K. Padma, Indian J. Pharm. Sci., 57(3), 126-129 (1995).
4 J. Thriveni, R. Rambabu, J. V Rao and S. Vidyadhara, Int. J. Res. Pharm. Chem., 3, 208-212 (2013).
5 V. R. Ram, P. N. Dave and H. S. Joshi, J. Chromatogr. Sci., 50, 721-726 (2012).   DOI
6 C. Vadloori and V. Tallada, J. Pharm. Res., 5(8), 3998-4000 (2012).
7 The United States Pharmacopoeia 35 National formulary 30. Eas-ton; R and Mc Nally Taunton; (2012).
8 Y. D. Dange, S. M. Honmane, S. D. Bhinge, V. R. Salunkhe and D. R. Jadge, Indian J. Pharm. Edu. Res., 52, S46-S52 (2018).
9 S. D. Bhinge, S. M. Malipatil and L. V. Sonawane, Acta Chim. Slov., 61, 580-586 (2014).
10 S. D. Bhinge, S. M. Malipatil, A. Jondhale and A. S. Savali, Asian J. Chem., 25, 981-985 (2013).   DOI
11 http://ccc.chem.pitt.edu/wipf/Web/LCMS%20trouble%20shooting.pdf, Accessed on 11/06/2021.
12 G. Kher, V. Ram, M. Kher and H. Joshi, Res. J. Pharm. Biol. Chem. Sci., 4, 365-377 (2013).
13 I. Velat, Z. Busic, M. J. Paic and V. Culic, BMC Pharmacol. Toxicol., 21, 57 (2020).   DOI
14 J. M. Sandall, J. S. Millership, P. S. Collier and J. C. McElnay, J. Chromatogr. B Anal. Tech. Biomed. Life Sci., 839, 36-44 (2006).   DOI
15 M. C. F. Ferraro, P. M. Castellano and T. S. Kaufman, J. Pharm. Biomed. Anal., 34, 305-314 (2004).   DOI
16 M. A. Hegazy, F. H. Metwaly, M. Abdelkawy and N. S Abdelwahab, J. Chromatogr. Sci., 49, 129-135 (2011).   DOI
17 N. Dubey, G. Patil, D. Kumar and J. Subhash, Int. J. Biomed. Pharm. Sci., 7, 38-41 (2013).
18 G Giebisch, Arzneimittelforschung, 35(1A), 336-342 (1985).
19 A. Qureshi and I. J. McGilveray, Drug Dev. Ind. Pharm., 24, 995-1005 (1998).   DOI
20 M. E. Bosch, A. J. R. Sanchez, F. S Rojas and C. B. Ojeda, Int. J. Pharm. Biol. Sci., 3, 168-181 (2013).
21 E. Dinc and O. ustunda?, Farmaco, 58, 1151-1161 (2003).   DOI
22 J. N. Tandel, Eura. J. Anal. Chem., 12, 385-394 (2017).   DOI
23 https://liverfellow.org/post/diuretics-ascites, Assessed 24 July 2021.
24 H. Patel and S. Solanki, Asian J. Pharm. Clin. Res., 5, 195-198 (2012).
25 S. Naveed, F. Qamar and S. Zainab, J. Innov. Pharm. Biol. Sci., 1, 97-101 (2014).
26 M. L. Luis, J. M. Garcia, F. Jimenez, A. J. Jimenez and J. J. Arias, J. AOAC Int., 82, 1054-1063 (1999).   DOI
27 S. D. Bhinge, S. M. Malipatil and L. V. Sonawane, Thai J. Pharm. Sci., 36, 63-71 (2012).
28 H. Patel and S. Solanki, Int. J. Pharm. Pharm. Sci., 4, 2-5 (2012).
29 S. Chawla, S. Ghosh, V. Sihorkar, R. Nellore, T. R. S. Kumar and N. R. Srinivas, Biomed. Chromatogr., 20, 349-357 (2006).   DOI
30 M. C. Ferraro, P. M. Castellano and T. S. Kaufman, J. Pharm. Biomed. Anal., 26, 443-451 (2001).   DOI
31 I. Youm and B. C. Youan, J. Anal. Meth. Chem., 2013, Article ID 207028 (2013).
32 R. Laxman, A. Ashish, J. Vinay, B. Sudhir and J. Deepti, Int. J. Res. Ayurveda Pharm., 1, 459-467 (2010).
33 M. Bhojani, K. Ketan and F. Shital, J. Pharm. Sci. Biosci. Res., 2, 144-147 (2012).
34 Q2A ICH guideline, Validation of analytical procedures text methodology, 2003.
35 Y. D. Dange, V. R. Salunkhe, S. D. Bhinge, B. R. Bhutkar and Y. H. Momin, Indian Drugs, 55, 61-66, (2017).
36 S. D. Bhinge, S. M. Malipatil, A. Jondhale, R. Hirave and A. S. Savali, E-J. Chem., 9, 1223-1229 (2012).   DOI
37 A. S. S. V. Reddy, M. Ahmed and A. S. K. Ashetty, Int. J. ChemTech Res., 5, 1876-1885 (2013).